CPBIO Holding Company Limited logo

CPBIO Holding Company Limited

3839.HK

HKSEHealthcareDrug Manufacturers - Specialty & Generic

Latest quote

HK$8.71

+HK$0.135 · +1.57%

Aug 21, 6:08 PM HKT

3839.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Chia Tai Enterprises International Limited primarily produces and distributes chlortetracycline (CTC) and related goods. Its extensive international reach covers Mainland China, the Asia Pacific region, the Americas, and Europe. The company's operations are divided into two distinct divisions: Biochemical and Industrial. The Biochemical division focuses on the manufacturing and supply of CTC premix and CTC hydrochloride products. These are employed as feed supplements to encourage livestock growth, prevent or cure animal illnesses, and improve feed conversion, sold under the brands Shihao and Citifac. Conversely, the Industrial segment handles the sales, rental, and maintenance of heavy construction machinery, encompassing items such as excavators, power generators, bulldozers, compactors, and their spare parts. This division also fabricates and markets carburetors and other automotive components for various automobile and motorcycle manufacturers. Founded in 1987, the company maintains its headquarters in Central, Hong Kong, and functions as a subsidiary of Charoen Pokphand Foods Public Company Limited.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
HK
CEO
Chawalit Na Muangtoun
Listed since
Jul 3, 2015
Employees
900

Market position

Day range

Current HK$8.71

52-week range

Current HK$8.71

Open
HK$8.70
Previous close
HK$8.575
Volume
1K
0.01× average
Average volume
122.38K
Average daily volume
Market cap
2.1B HKD
Beta
3.99
Market reference 1
50-day average
HK$8.8785
-1.90% below average
200-day average
HK$7.5828
+14.87% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
243.97M USD
P/E (TTM)
11.49×
P/B (TTM)
0.91×
P/S (TTM)
0.63×
EV / EBITDA
5.05×
Earnings yield
13.61%
Free cash flow yield
11.88%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
16.60%
Operating margin
7.07%
Net margin
5.76%
Return on equity
11.58%
Return on assets
6.95%
Return on invested capital
8.95%

Financial health

Debt / equity
0.26×
Current ratio
1.63×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends27%16%4%-7%Gross margin, FY2021: 24.41%Gross margin, FY2022: 24.61%Gross margin, FY2023: 17.35%Gross margin, FY2024: 15.90%Gross margin, FY2025: 14.45%Operating margin, FY2021: 3.49%Operating margin, FY2022: 3.06%Operating margin, FY2023: -2.61%Operating margin, FY2024: 3.63%Operating margin, FY2025: 7.26%Net margin, FY2021: 13.74%Net margin, FY2022: -4.19%Net margin, FY2023: 1.47%Net margin, FY2024: 3.63%Net margin, FY2025: 5.98%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 24.41%. Gross margin FY2022 24.61%. Gross margin FY2023 17.35%. Gross margin FY2024 15.90%. Gross margin FY2025 14.45%. Operating margin FY2021 3.49%. Operating margin FY2022 3.06%. Operating margin FY2023 -2.61%. Operating margin FY2024 3.63%. Operating margin FY2025 7.26%. Net margin FY2021 13.74%. Net margin FY2022 -4.19%. Net margin FY2023 1.47%. Net margin FY2024 3.63%. Net margin FY2025 5.98%.

Income trends

Revenue

536.71M USD+74.40%

Operating income

38.95M USD+248.47%

Net income

32.1M USD+187.45%
Income trends across reported periods591.05M USD373.69M USD156.34M USD−61.02M USDRevenue, FY2021: 142.41M USDRevenue, FY2022: 159.24M USDRevenue, FY2023: 173.98M USDRevenue, FY2024: 307.75M USDRevenue, FY2025: 536.71M USDOperating income, FY2021: 4.97M USDOperating income, FY2022: 4.88M USDOperating income, FY2023: −4.54M USDOperating income, FY2024: 11.18M USDOperating income, FY2025: 38.95M USDNet income, FY2021: 19.56M USDNet income, FY2022: −6.68M USDNet income, FY2023: 2.55M USDNet income, FY2024: 11.17M USDNet income, FY2025: 32.1M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 142.41M USD. Revenue FY2022 159.24M USD. Revenue FY2023 173.98M USD. Revenue FY2024 307.75M USD. Revenue FY2025 536.71M USD. Operating income FY2021 4.97M USD. Operating income FY2022 4.88M USD. Operating income FY2023 −4.54M USD. Operating income FY2024 11.18M USD. Operating income FY2025 38.95M USD. Net income FY2021 19.56M USD. Net income FY2022 −6.68M USD. Net income FY2023 2.55M USD. Net income FY2024 11.17M USD. Net income FY2025 32.1M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue536.71M USD307.75M USD173.98M USD159.24M USD142.41M USD
Cost of goods sold459.16M USD258.81M USD140.21M USD120.05M USD107.65M USD
Gross profit77.55M USD48.93M USD30.19M USD39.19M USD34.76M USD
Selling, general, and administrative38.6M USD37.76M USD38.3M USD34.31M USD29.79M USD
Operating expenses38.6M USD37.76M USD34.72M USD34.31M USD29.79M USD
Interest income926.37K USD1.39M USD1.15M USD368K USD76K USD
Interest expense1.7M USD2.22M USD1.95M USD994K USD648K USD
Depreciation and amortization9.33M USD6.34M USD6.39M USD6.93M USD7.41M USD
Operating income38.95M USD11.18M USD−4.54M USD4.88M USD4.97M USD
Net income32.1M USD11.17M USD2.55M USD−6.68M USD19.56M USD

Company facts updated Aug 24, 2026.

3839.HK peers

ETFs holding 3839.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research 3839.HK

research.disclaimer